MX2021008248A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2021008248A
MX2021008248A MX2021008248A MX2021008248A MX2021008248A MX 2021008248 A MX2021008248 A MX 2021008248A MX 2021008248 A MX2021008248 A MX 2021008248A MX 2021008248 A MX2021008248 A MX 2021008248A MX 2021008248 A MX2021008248 A MX 2021008248A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
multibranched
copolymer
polyether
aqueous solution
Prior art date
Application number
MX2021008248A
Other languages
English (en)
Spanish (es)
Inventor
Christophe Roberge
Juliette Serindoux
Fang Liu
Jean Manuel Cros
Murielle Oster
Charlotte Molinier
Sylvestre Grizot
Feifei Ng
Elise Guégain
Marie - Emérentienne CAGNON
Noriega Adolfo Lopez
Tjasa Vrlinic
Original Assignee
Medincell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medincell filed Critical Medincell
Publication of MX2021008248A publication Critical patent/MX2021008248A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021008248A 2019-01-08 2020-01-08 Composicion farmaceutica. MX2021008248A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1900258.3A GB201900258D0 (en) 2019-01-08 2019-01-08 Pharmaceutical composition
PCT/EP2020/050333 WO2020144239A1 (en) 2019-01-08 2020-01-08 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2021008248A true MX2021008248A (es) 2021-10-13

Family

ID=65528088

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008248A MX2021008248A (es) 2019-01-08 2020-01-08 Composicion farmaceutica.

Country Status (25)

Country Link
US (3) US12485139B2 (cg-RX-API-DMAC7.html)
EP (2) EP3908321B1 (cg-RX-API-DMAC7.html)
JP (2) JP7680355B2 (cg-RX-API-DMAC7.html)
KR (2) KR102958459B1 (cg-RX-API-DMAC7.html)
CN (1) CN113543775B (cg-RX-API-DMAC7.html)
AU (1) AU2020205438B9 (cg-RX-API-DMAC7.html)
BR (1) BR112021013456A2 (cg-RX-API-DMAC7.html)
CA (1) CA3125372A1 (cg-RX-API-DMAC7.html)
DK (1) DK3908321T3 (cg-RX-API-DMAC7.html)
EA (1) EA202191603A1 (cg-RX-API-DMAC7.html)
ES (1) ES2968432T3 (cg-RX-API-DMAC7.html)
FI (1) FI3908321T3 (cg-RX-API-DMAC7.html)
GB (1) GB201900258D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20231667T1 (cg-RX-API-DMAC7.html)
HU (1) HUE064916T2 (cg-RX-API-DMAC7.html)
LT (1) LT3908321T (cg-RX-API-DMAC7.html)
MX (1) MX2021008248A (cg-RX-API-DMAC7.html)
PH (1) PH12021551642A1 (cg-RX-API-DMAC7.html)
PL (1) PL3908321T3 (cg-RX-API-DMAC7.html)
PT (1) PT3908321T (cg-RX-API-DMAC7.html)
RS (1) RS65067B1 (cg-RX-API-DMAC7.html)
SI (1) SI3908321T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400011T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020144239A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104704B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301609A (en) * 2020-10-01 2023-05-01 Standard Millox Pharmaceuticals Oy Hydrogel material
MX2024001681A (es) 2021-08-05 2024-03-04 Medincell S A Composicion farmaceutica.
AU2024381207A1 (en) 2023-11-17 2026-05-14 Institut National de la Santé et de la Recherche Médicale Antineoplastic combinations
WO2026013080A1 (en) 2024-07-08 2026-01-15 InnoCore Technologies Holding B.V. Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2016A (en) 1841-03-26 Mode of constructing fireplaces and chimney-staoks ii
US5225521A (en) 1991-12-31 1993-07-06 E. I. Du Pont De Nemours And Company Star-shaped hydroxyacid polymers
FR2741628B1 (fr) 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
WO1998012274A1 (en) 1996-09-23 1998-03-26 Chandrashekar Pathak Methods and devices for preparing protein concentrates
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
US7265186B2 (en) 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
CA2463158C (en) 2001-10-30 2013-07-30 Novartis Ag Depot formulations of iloperidone and a star polymer
US7649023B2 (en) 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US20050255091A1 (en) 2004-05-14 2005-11-17 Loomis Gary L Hydrogels for biomedical applications
JP5539725B2 (ja) 2006-11-27 2014-07-02 アクタマックス サージカル マテリアルズ リミテッド ライアビリティ カンパニー 分岐末端反応物及びそれから製造されるポリマーヒドロゲル組織接着剤
US9248165B2 (en) * 2008-11-05 2016-02-02 Hancock-Jaffe Laboratories, Inc. Composite containing collagen and elastin as a dermal expander and tissue filler
US20110070320A1 (en) 2009-09-23 2011-03-24 Soonkap Hahn Biodegradable thermoresponsive 3-arm polyethylene glycol poly(lactide-co-glycolide) copolymer for ginseng administration
MY165655A (en) * 2010-12-29 2018-04-18 Medincell Biodegradable drug delivery compositions
CN102432852B (zh) * 2011-08-25 2013-10-16 复旦大学 一种聚乳酸基立构复合交联共聚物及其制备方法
KR102189442B1 (ko) 2012-06-27 2020-12-11 메딘셀 에스.에이. 소수성 조성물용 생분해성 약물 전달
AU2014252689A1 (en) 2013-04-11 2015-10-15 Commonwealth Scientific And Industrial Research Organisation Composition for controlled delivery of bioactive agents
CN103342805B (zh) * 2013-07-26 2017-03-29 中国科学院长春应用化学研究所 非线性聚乙二醇‑聚酯共聚物、非线性聚乙二醇‑聚酯共聚物胶束及载药胶束的制备方法
CN106535886A (zh) * 2014-04-21 2017-03-22 赫伦治疗有限公司 长效聚合物输送系统
CN103976976B (zh) 2014-06-03 2016-05-11 长春理工大学 一种包载重组人生长激素缓释药物微囊的制法
AU2016355236C1 (en) * 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
CN106543454B (zh) 2016-11-25 2019-05-28 山东师范大学 一种低溶胀可生物降解医用光聚合型水凝胶及其制备方法
CN106832844B (zh) 2017-02-10 2018-11-20 四川大学 一种四臂peg-pcl、氧化石墨烯复合材料及其制备方法
LT3655038T (lt) 2017-07-17 2025-02-10 Medincell S.A. Farmacinė kompozicija
CN108586775B (zh) 2018-05-04 2019-11-12 四川大学 可用于眼内长期填充的原位交联超支化聚醚类水凝胶及其制备方法

Also Published As

Publication number Publication date
EP3908321A1 (en) 2021-11-17
JP7680355B2 (ja) 2025-05-20
CA3125372A1 (en) 2020-07-16
ZA202104704B (en) 2024-11-27
FI3908321T3 (fi) 2024-01-11
EP4289429A2 (en) 2023-12-13
KR102958459B1 (ko) 2026-04-29
PH12021551642A1 (en) 2022-05-23
PT3908321T (pt) 2024-01-15
SI3908321T1 (sl) 2024-03-29
AU2020205438B8 (en) 2025-03-27
US20260115226A1 (en) 2026-04-30
DK3908321T3 (da) 2024-01-15
AU2020205438A1 (en) 2021-07-29
JP2022517939A (ja) 2022-03-11
EP3908321B1 (en) 2023-11-15
CN113543775B (zh) 2023-11-24
JP2025066716A (ja) 2025-04-23
US20220118003A1 (en) 2022-04-21
US20240293444A1 (en) 2024-09-05
AU2020205438B2 (en) 2025-02-06
WO2020144239A1 (en) 2020-07-16
GB201900258D0 (en) 2019-02-27
CN113543775A (zh) 2021-10-22
US12427165B2 (en) 2025-09-30
SMT202400011T1 (it) 2024-03-13
EP4289429A3 (en) 2024-03-20
BR112021013456A2 (pt) 2021-09-14
RS65067B1 (sr) 2024-02-29
ES2968432T3 (es) 2024-05-09
PL3908321T3 (pl) 2024-03-25
US12485139B2 (en) 2025-12-02
KR20210113251A (ko) 2021-09-15
KR20260061472A (ko) 2026-05-06
HRP20231667T1 (hr) 2024-03-15
HUE064916T2 (hu) 2024-04-28
LT3908321T (lt) 2024-01-25
EA202191603A1 (ru) 2021-10-20
AU2020205438B9 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
CL2020002252A1 (es) Formulación oftálmica.
CL2013001942A1 (es) Composicion de suministro de farmaco biodegradable que comprende a) un copolimero de tres bloques biodegradable, b) un copolimero de dos bloques biodegradable, y c) cuando menos un principio farmaceuticamente activo; metodo para su preparacion: y su uso.
AR059097A1 (es) Tratamiento a largo plazo de la infeccion por vih
MX2019007956A (es) Liberacion autorregulada de ingrediente farmaceutico activo.
ZA202104704B (en) Pharmaceutical composition
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
AR038575A1 (es) Formulacion oftalmica con nueva composicion de goma
AR062046A1 (es) Soluciones oftalmicas
AR048705A1 (es) Composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
CL2012000446A1 (es) Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios.
CL2013000423A1 (es) Forma de dosificacion farmaceutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacarido anionico y un oxido de polialquileno, en donde el ingrediente activo esta presente en una matriz de liberacion controlada comprendiendo el polisacarido anionico y el oxido de polialquileno.
AR054227A1 (es) Composicion de principios activos
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
AR047205A1 (es) Composiciones oftalmicas que contienen una combinacion sinergica de tres polimeros
AR117655A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal
MX2014008283A (es) Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta.
CO2018010549A2 (es) Composición administrable oralmente
MX385380B (es) Formulacion topica para promover la curacion de heridas.
BRPI0922806B8 (pt) composição farmacêutica oral compreendendo bendamustina
AR065316A1 (es) Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales
ECSP034915A (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
ES2325291A1 (es) "uso de un extracto de silybum marianum"
AR033596A1 (es) Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
CL2012000061A1 (es) Composición oftálmica acuosa estéril que comprende un copolímero de bloque de óxido de etileno óxido de butileno (eo-bo) y una galactomanana; y uso para el tratamiento del ojo seco.